A Study of Barzolvolimab in Patients With Atopic Dermatitis

Inclusion Criteria:

1. Male or female ≥ 18 years of age

2. Diagnosis of chronic atopic dermatitis (AD) for at least 1 year

3. Onset of symptoms at least 1 year prior and current symptoms consistent withmoderate to severe AD as defined by:

4. EASI ≥ 12 at Visit 1 and EASI ≥ 16 at Visit 2

5. Body Surface Area of Involvement (BSA) ≥ 10% at Visit 1 and Visit 2

6. IGA score ≥ 3 at Visit 1 and Visit 2

7. Severe itch, defined by weekly average of daily PP-NRS score of ≥ 5, during the 7 days prior to treatment

8. Documented history of inadequate response to treatment with topical medications orfor whom topical medications are otherwise medically inadvisable.

9. Willing and able to complete a daily symptom electronic diary for the duration ofthe study and adhere to the study visit schedule.

Exclusion Criteria:

1. Any other active pruritic skin diseases that would confound AD assessments based onthe Investigator's clinical judgment.

2. Phototherapy with ultraviolet (UV) A or UVB within 4 weeks of Visit 1.

3. Planned or anticipated use of any prohibited medications at any time during thestudy.

4. Prior receipt of barzolvolimab or other anti-KIT therapy. There are additionalcriteria that your study doctor will review with you to confirm you are eligible forthe study.